

FORM PTO-1449		US Dept. of Commerce Patent and Trademark Office		ATTORNEY DOCKET NO. 4121-135		SERIAL NO. 10/049,404	
INFORMATION DISCLOSURE STATEMENT (use several sheets if necessary)				APPLICANT Michaela Arndt		FILING DATE February 5, 2002	
				GROUP 1644		Not yet assigned.	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
C.C.	AA	5,643,759	7/1/97	Pfreundschuh			
C.C.	AB	6,294,167	9/25/01	Lindhofer et al.			
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AC	DE 43 37 197	10/30/93	Germany			
	AD	DE 195 31 346	8/25/95	Germany			
	AE	DE 198 38 967	2/6/98	Germany			
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
C.C.	AF	XP-002115487. "Bispecific CD3 X CD19 Diabody for T Cell-Mediated Lysis of Malignant Human B Cells." Kiprianov et al. Int. J. Cancer: 77, 763-771 (1998).					
	AG	"Anti- CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin's Disease." Hartmann et al., Leuk & Lyph., 1998. Vol 31. patent. 385-392.					
	AH	XP 000653169. 609. Klimka et al.					
C.C.	AI	XP-002153101. "A bispecific diabody that mediates natural killer cell cytotoxicity against exnotransplantated human Hodgkin's tumors." Arndt et al. Blood, Vol. 94, No. 8 (October 15), 1999: patent 2562-2568.					
EXAMINER							
DATE CONSIDERED							